spacer
home > ebr > spring 2009 > dispersions deliver results
PUBLICATIONS
European Biopharmaceutical Review

Dispersions Deliver Results

 

Low-solubility, high-permeability compounds make up nearly one-third of all active pharmaceutical ingredients (APIs) in early development. For many compounds in this class, oral absorption can be achieved by enhancing solubility using solubilisation technologies. This article is an overview of current options in solid form solubilisation technologies, including several novel platforms that are based on nanocrystals and drug/polymer solid amorphous dispersions. The platforms discussed are spray-dried dispersions (SDDs), nanoadsorbates and crystallised spray-dried dispersions (CSDDs). Strategies are described to guide rational selection of the optimum technology for solubility enhancement.

Poor oral bioavailability due to the low aqueous solubility of potential drug candidates is an increasingly common challenge facing the pharmaceutical industry (1). Nearly one-third of compounds in early development have poor bioavailability due to low solubility, representing a significant loss in economic and therapeutic opportunity (2). Although they may not fit the ‘rule of five’, many of these low-solubility compounds – which fall into Class II of the Biopharmaceutics Classification System (BCS) – have the potential to be safe and efficacious, so it is critical that further development is not halted by solubility limitations (3).

In response to this problem, multiple drug-delivery technologies have been advanced in an attempt to solubilise such molecules in order to enhance their oral bioavailability. Solubilisation technologies can improve oral absorption of BCS Class II compounds by:

  • Increasing dissolution rate
  • Increasing concentration of dissolved drug (above the equilibrium concentration of the solubility of bulk crystalline drug)
  • Maintaining the enhanced dissolved drug concentration

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
1
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Dr David T Vodak is a Senior Research Chemist and Group Leader at Bend Research Inc, a private research and development laboratory in Bend, Oregon. David holds a PhD in materials chemistry from the University of Michigan-Ann Arbor and a BA in Chemistry from Willamette University in Salem, Oregon. After completing his post-doctoral work at the Scripps Research Institute in La Jolla, California, David joined Bend Research Inc, where he has worked on novel technology development. His areas of expertise are the research and development of novel pharmaceutical drug-delivery systems for the delivery of low-solubility compounds.

Dr Dwayne T Friesen is the Vice President of Research at Bend Research Inc. Dwayne holds a PhD in physical chemistry from Oregon State University in Corvallis, Oregon, and a BS in Chemistry from California State College – Bakersfield. He holds 44 US patents and has 15 scientific publications. Dwayne directs the research and development for novel drug-delivery systems and pharmaceutical formulations.

spacer
David T Vodak
spacer
spacer
spacer
Dwayne T Friesen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Synpromics expands facilities to meet demand for revolutionary gene control technology

Edinburgh, UK, 11th September 2017 - Synpromics Ltd, the leader in gene control and synthetic promoter development, today moves to new world-class facilities at the Roslin Innovation Centre. Synpromics is expanding to meet increasing global demand for its cutting-edge gene control technology, and is the first company to move into the new custom-built centre based at the University of Edinburgh’s Easter Bush Campus.
More info >>

White Papers

Delivering Fit For Purpose Biomanufacturing CHO Cell Lines

Fujifilm Diosynth Biotechnologies

The challenge during mammalian cell line development is to identify and isolate stable, high expressing cell lines producing product with the appropriate critical product quality attributes rapidly, reproducibly and with relative ease. Obtaining a host cell line that inherently exhibits desirable biomanufacturing attributes can therefore have a significantly positive effect on the identification of recombinant cell lines with desired traits during cell line development screens. In this study, we demonstrate that it is possible to exploit intrinsic heterogeneity within host cell populations and identify host cell lines which are more “fit for purpose”.
More info >>

 
Industry Events

ASPIRE: International EDGE Conference

28 February - 1 March 2018, The Vox Conference Centre, Birmingham

The ASPIRE international conference is taking place on the 28th February and 1st March 2018 at the Vox Conference Centre in Birmingham. The conference brings together members of the research community including research professionals from the NHS, Clinical Trial Networks and international organisations. The ASPIRE conference will allow delegates to share knowledge and best practise with the focus on enhancing the efficiency and productivity of clinical research across the UK and beyond.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement